FDA Approves First Targeted Therapy for Rare Skin Disease

The FDA has approved Lisraya, the first targeted oral therapy for adults with dermatomyositis, a rare autoimmune skin and muscle disease. The approval follows a successful Phase 3 trial demonstrating significant improvement in patients and offers an alternative to chronic high-dose steroids.

This Wire brief sits within Fusion42's coverage of Biotech, and 10 sources have reported it between 27 Aug 2026 and 2 Sep 2026.